Literature DB >> 21167314

The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats.

Yan Wang1, Mingsheng Zhang, Yunfeng Liu, Yu Liu, Min Chen.   

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous and competitive inhibitor of nitric oxide synthase. Plasma level of ADMA is elevated in patients with hypertension. In these patients, plasma ADMA levels are correlated with the severity of endothelial dysfunction. Nebivolol, a highly selective blocker of beta1-adrenergic receptors, is the only beta-blocker known to induce vascular production of NO. There is little data on the effect of nebivolol on ADMA system in spontaneously hypertensive rats (SHR). In this study SHR and age-matched Wister-Kyoto (WKY) rats were randomly divided into 4 groups: SHR treated with nebivolol (8 mg/kg/day, i.g.); SHR treated with Atenolol (80 mg/kg/day, i.g.); SHR control group; WKY control group. Nebivolol induced an acute and significant reduction in systolic blood pressure in SHR. Compared with WKY, plasma ADMA was elevated significantly, while NOS activity and NO were decreased in SHR. In aorta and mesenteric artery of SHR, the expression of eNOS and DDAH 2 reduced, but expression of PRMT 1 increased. And ROS level in aorta also increased. Nebivolol increased plasma NO and NOS activity, attenuated ADMA level. The expression of eNOS and DDAH 2 were up-regulated, PRMT 1 expression were down-regulated after nebivolol treatment. Nebivolol also reduced aortic ROS. Our results indicate that nebivolol reduces plasma ADMA level in SHR by increasing its hydrolysis and reducing its generation. Nebivolol affects ADMA system not only from metabolism but also from generation. The influence of nebivolol on ADMA is complex, and the mechanism remains to be investigated.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167314     DOI: 10.1016/j.vph.2010.12.001

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  6 in total

1.  Nebivolol does not protect against 5/6 ablation/infarction induced chronic kidney disease in rats - comparison with angiotensin II receptor blockade.

Authors:  Jennifer M Sasser; Natasha C Moningka; Tatsiana Tsarova; Chris Baylis
Journal:  Life Sci       Date:  2012-06-19       Impact factor: 5.037

Review 2.  Clinical Significance of Endothelial Dysfunction in Essential Hypertension.

Authors:  Eugenia Gkaliagkousi; Eleni Gavriilaki; Areti Triantafyllou; Stella Douma
Journal:  Curr Hypertens Rep       Date:  2015-11       Impact factor: 5.369

Review 3.  The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.

Authors:  James Leiper; Manasi Nandi
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

4.  Probucol Protects Against Asymmetric Dimethylarginine-Induced Apoptosis in the Cultured Human Brain Microvascular Endothelial Cells.

Authors:  Jiwei Ma; Shupeng Zhao; Guojun Gao; Haigang Chang; Pengju Ma; Baozhe Jin
Journal:  J Mol Neurosci       Date:  2015-08-09       Impact factor: 3.444

5.  Short-term esmolol improves coronary artery remodeling in spontaneously hypertensive rats through increased nitric oxide bioavailability and superoxide dismutase activity.

Authors:  Ana Arnalich-Montiel; María Carmen González; Emilio Delgado-Baeza; María Jesús Delgado-Martos; Luis Condezo-Hoyos; Antonia Martos-Rodríguez; Pilar Rodríguez-Rodríguez; Begoña Quintana-Villamandos
Journal:  Biomed Res Int       Date:  2014-03-26       Impact factor: 3.411

Review 6.  Toxic Dimethylarginines: Asymmetric  Dimethylarginine (ADMA) and Symmetric  Dimethylarginine (SDMA).

Authors:  You-Lin Tain; Chien-Ning Hsu
Journal:  Toxins (Basel)       Date:  2017-03-06       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.